The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo

International Journal of Cancer

Volumn 122, Issue 7, 2008, Pages 1639-1644

  Liu, Jun Feng ^a,d   Zhang, Shao Wei ^a   Jamieson, Glyn G ^b   Zhu, Gui Jun ^a   Wu, Tie Cheng ^a   Zhu, Tie Nian ^a   Shan, Bao En ^a   Drew, Paul A ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d Medical University   (China)

Author keywords

Apoptosis; Cyclooxygenase; Esophagus; Meloxicam; Nonsteroidal anti inflammatory drugs; Prostaglandin; Squamous cell carcinoma

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELOXICAM; MESSENGER RNA; CYCLOOXYGENASE 2 INHIBITOR; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; DRUG ANTAGONISM; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; MALE; MIDDLE AGED; NF-KAPPA B; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZINES; THIAZOLES;

EID: 39649096086     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23288     Document Type: Article

References (32)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Lerut T. Esophageal carcinoma: past and present studies. Eur J Surg Oncol 1999;22:317-23.
3. Kok TC, Tilanus HW. Neoadjuvant treatment in esophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group. Eur J Surg Oncol 1999;22:323-5.
4. Becker HD. Esophageal cancer, early disease: diagnosis and current treatment. World J Surg 1994;18:331-8.
5. Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the esophagus and gastric cardia in Hebei, China. Br J Surg 2004;91:90-8.
6. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
7. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-19.
8. Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:545-9.
9. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
10. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58: 2929-34.
11. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
12. France M, Drew PA, Dodd T, Watson DI. Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Dis Esoph 2004;17:36-40.
13. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002;13:127-137.
14. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215:1-20.
15. Liu JF, Jamieson GG, Drew PA, Zhu GJ, Zhang SW, Zhu TN, Shan BE, Wang QZ. Aspirin induces apoptosis in esophageal cancer cells by inhibiting the pathway of NF-κB downstream regulation of cyclooxygenase-2. ANZ J Surg 2005;75:1011-16.
16. Liu S, Khemlani LS, Shapiro RA, Johnson ML, Liu K, Geller DA, Watlins SC, Goyert SM, Billiar TR. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect Immunol 1998;66:5089-98.
17. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
18. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
19. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
20. Liu JF, Jamieson GG, Wu TC, Zhang SW, Wang QZ, Drew PA. Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. Dis Esoph 2006;19:350-4.
21. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000;6:1229-38.
22. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
23. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-18.
24. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-23.
25. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
26. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, Tanaka M. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κ B activation. Oncogene 2000;19:1225-31.
27. Rinder HM, Tracey JB, Souhrada M, Wang C, Gagnier RP, Wood CC. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J Clin Pharmacol 2002;42:881-6.
28. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (κ)B kinase-β. Nature 1998;396:77-80.
29. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor κ B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005;103:2485-90.
30. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T. Suppression of metastasis by nuclear factor κB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004;95:18-24.
31. Heath EI, Canto MI, Wu TT, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545-57.
32. Limburg PJ, Wei WQ, Ahnen DJ, Qiao YL, Hawk ET, Wang GQ, Giffen CA, Wang GQ, Roth MJ, Lu NN, Korn EL, Ma YR, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005;129:863-73.